Dopamine receptor D4 (DRD4) polymorphisms with reduced functional potency intensify atrophy in syndrome-specific sites of frontotemporal dementia
- PMID: 31003069
- PMCID: PMC6475809
- DOI: 10.1016/j.nicl.2019.101822
Dopamine receptor D4 (DRD4) polymorphisms with reduced functional potency intensify atrophy in syndrome-specific sites of frontotemporal dementia
Abstract
Objective: We aimed to understand the impact of dopamine receptor D4 (DRD4) polymorphisms on neurodegeneration in patients with dementia. We hypothesized that DRD4dampened-variants with reduced functional potency would be associated with greater atrophy in regions with higher receptor density. Given that DRD4 is concentrated in anterior regions of the limbic and cortical forebrain we anticipated genotype effects in patients with a more rostral pattern of neurodegeneration.
Methods: 337 subjects, including healthy controls, patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD) underwent genotyping, structural MRI, and cognitive/behavioral testing. We conducted whole-brain voxel-based morphometry to examine the relationship between DRD4 genotypes and brain atrophy patterns within and across groups. General linear modeling was used to evaluate relationships between genotype and cognitive/behavioral measures.
Results: DRD4 dampened-variants predicted gray matter atrophy in disease-specific regions of FTD in anterior cingulate, ventromedial prefrontal, orbitofrontal and insular cortices on the right greater than the left. Genotype predicted greater apathy and repetitive motor disturbance in patients with FTD. These results covaried with frontoinsular cortical atrophy. Peak atrophy patterned along regions of neuroanatomic vulnerability in FTD-spectrum disorders. In AD subjects and controls, genotype did not impact gray matter intensity.
Conclusions: We conclude that DRD4 polymorphisms with reduced functional potency exacerbate neuronal injury in sites of higher receptor density, which intersect with syndrome-specific regions undergoing neurodegeneration in FTD.
Keywords: Anterior cingulate cortex; Apathy; DRD(4); Frontotemporal dementia; Insula; Salience network.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Figures




Similar articles
-
More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer's disease.J Alzheimers Dis. 2015;44(2):635-47. doi: 10.3233/JAD-141230. J Alzheimers Dis. 2015. PMID: 25322925
-
Alzheimer's disease and frontotemporal dementia exhibit distinct atrophy-behavior correlates: a computer-assisted imaging study.Acad Radiol. 2003 Dec;10(12):1392-401. doi: 10.1016/s1076-6332(03)00543-9. Acad Radiol. 2003. PMID: 14697007
-
Two insular regions are differentially involved in behavioral variant FTD and nonfluent/agrammatic variant PPA.Cortex. 2016 Jan;74:149-57. doi: 10.1016/j.cortex.2015.10.012. Epub 2015 Nov 14. Cortex. 2016. PMID: 26673947 Free PMC article.
-
Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a systematic review and meta-analysis.Brain Imaging Behav. 2020 Dec;14(6):2799-2816. doi: 10.1007/s11682-019-00099-3. Brain Imaging Behav. 2020. PMID: 31011951 Free PMC article.
-
A systematic review of the prevalence of depression, anxiety, and apathy in frontotemporal dementia, atypical and young-onset Alzheimer's disease, and inherited dementia.Int Psychogeriatr. 2023 Sep;35(9):457-476. doi: 10.1017/S1041610220001118. Epub 2020 Jul 20. Int Psychogeriatr. 2023. PMID: 32684177
Cited by
-
Effect of Functional BDNF and COMT Polymorphisms on Symptoms and Regional Brain Volume in Frontotemporal Dementia and Corticobasal Syndrome.J Neuropsychiatry Clin Neurosci. 2020 Fall;32(4):362-369. doi: 10.1176/appi.neuropsych.19100211. Epub 2020 May 13. J Neuropsychiatry Clin Neurosci. 2020. PMID: 32397876 Free PMC article.
-
Tolcapone Treatment for Cognitive and Behavioral Symptoms in Behavioral Variant Frontotemporal Dementia: A Placebo-Controlled Crossover Study.J Alzheimers Dis. 2020;75(4):1391-1403. doi: 10.3233/JAD-191265. J Alzheimers Dis. 2020. PMID: 32444540 Free PMC article. Clinical Trial.
-
Association Between DRD2 and DRD4 Polymorphisms and Eating Disorders in an Italian Population.Front Nutr. 2022 Mar 14;9:838177. doi: 10.3389/fnut.2022.838177. eCollection 2022. Front Nutr. 2022. PMID: 35369087 Free PMC article.
References
-
- Agosta F., Vossel K.A., Miller B.L., Migliaccio R., Bonasera S.J., Filippi M., Boxer A.L., Karydas A., Possin K.L., Gorno-Tempini M.L. Apolipoprotein E E4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc. Natl. Acad. Sci. U. S. A. 2009;106:2018–2022. - PMC - PubMed
-
- Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Boxer A.L., Dickson D.W., Grossman M., Hallett M., Josephs K., Kerterz A., Lee S.E., Miller B.L., Reich S.G., Riley D.E., Tolosa E., Tröster A.I., Vidailhet M., Weiner W.J. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503. - PMC - PubMed
-
- Asghari V., Schoots O., Van Kats S., Ohara K., Jovanovic V., Guan H.-C., Bunzow J.R., Petronis A., Van Tol H.H.M. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol. Pharm. 1994;46:364–373. - PubMed
-
- Asghari V., Sanyal S., Buchwaldt S., Paterson A., Jovanovic V., Van Tol H.H.M. Modulation of intercellular cyclic AMP levels by different human dopamine receptor variants. J. Neurochem. 1995;65:1157–1165. - PubMed
-
- Butler P.M., Matthews L.J. Novelty-seeking DRD4 polymorphisms are associated with human migration distance out-of-Africa after controlling for neutral population gene structure. Am. J. Phys. Anthr. 2011;145:382–389. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- RC1 AG035610/AG/NIA NIH HHS/United States
- U24 AG021886/AG/NIA NIH HHS/United States
- R01 AG052496/AG/NIA NIH HHS/United States
- T32 AG023481/AG/NIA NIH HHS/United States
- P01 AG019724/AG/NIA NIH HHS/United States
- R01 MH097268/MH/NIMH NIH HHS/United States
- K24 DC015544/DC/NIDCD NIH HHS/United States
- R01 AG026938/AG/NIA NIH HHS/United States
- K23 AG045289/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- U01 AG052943/AG/NIA NIH HHS/United States
- P30 NS062691/NS/NINDS NIH HHS/United States
- R01 AG057204/AG/NIA NIH HHS/United States
- R01 NS100440/NS/NINDS NIH HHS/United States
- R56 NS050915/NS/NINDS NIH HHS/United States
- R01 NS050915/NS/NINDS NIH HHS/United States